Drug news
Phase III study shows RLX 030 (Novartis) effective against Dyspnea in Heart Failure patients
RLX 030 (serelaxin), from Novartis, may be more effective for relieving Dyspnea in Heart Failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from the RELAX-AHF trial. RELAX-AHF was a double blinded, randomised, placebo controlled trial in which 1161 AHF patients from 96 sites were randomised to 48 hour infusion of serelaxin or placebo within 16 hours of presentation.
Serelaxin induced similar dyspnea relief in HFpEF and HFrEF patients at day 5 but was more effective in the HFpEF group in the first 24 hours. There were no differences between HFpEF and HFrEF patients in the effect of serelaxin on the secondary endpoints of cardiovascular death or rehospitalisation for heart or renal failure, and days alive and out of hospital through day 60. Results were presented at the Heart Failure Congress.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins